The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Castro, Daniela [1 ]
Tripathi, Nishita [2 ]
Sayegh, Nicolas [2 ]
Gebrael, Georges [2 ]
Li, Xiaochen [1 ]
Meza, Luis [1 ]
Zengin, Zeynep [1 ]
Chehrazi-Raffle, Alex [1 ]
Govindarajan, Ameish [1 ]
Dizman, Nazli [1 ,3 ]
Ebrahimi, Hedyeh [1 ]
Chawla, Neal [1 ]
Mercier, Benjamin [1 ]
Hsu, Joann [1 ]
Shi, Jessica [1 ]
Philip, Errol [4 ]
Bergerot, Cristiane [5 ]
Barragan-Carrillo, Regina [1 ,6 ]
Pal, Sumanta [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
[2] Univ Utah, Huntsman Canc Inst, Div Med Oncol, Salt Lake City, UT USA
[3] Yale Univ, Dept Internal Med, Sch Med, New Haven, CT USA
[4] Univ Calif San Francisco, San Francisco, CA USA
[5] Ctr Canc Brasilia CETTRO, Inst Unity Ensino & Pesquisa, Brasilia, DF, Brazil
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico
来源：
ONCOLOGIST | 2023年 / 28卷
关键词：
insurance status; clinical outcomes; disparities; social determinants of health;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
45
引用
收藏
页码：S5 / +
页数：2
相关论文
共 50 条
  • [31] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS' SEQUENTIALLY TREATED WITH TARGETED THERAPIES (TTS)
    Procopio, G.
    Verzoni, E.
    Testa, I.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [32] Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma
    McAlister, Renee K.
    Aston, Jonathan
    Pollack, Megan
    Du, Liping
    Koyama, Tatsuki
    Chism, David D.
    ONCOLOGIST, 2018, 23 (06): : 686 - 692
  • [33] Prognostic factors for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC): Results from the French randomized phase II study TORAVA.
    Escudier, B. J.
    Negrier, S.
    Perol, D.
    Gravis, G.
    Delva, R.
    Bay, J.
    Geoffrois, L.
    Legouffe, E.
    Metzger, S.
    Ferlay, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
    Kucharz, Jakub
    Dumnicka, Paulina
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Wiechno, Pawel
    MEDICAL ONCOLOGY, 2019, 36 (02)
  • [35] Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients
    Sjoquist, Katrin Marie
    Bokemeyer, Carsten
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Adams, Richard
    Punt, Cornelis J. A.
    Van Cutsem, Eric
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Heinemann, Volker
    Sougklakos, Ioannis
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
    Jakub Kucharz
    Paulina Dumnicka
    Beata Kusnierz-Cabala
    Tomasz Demkow
    Pawel Wiechno
    Medical Oncology, 2019, 36
  • [37] Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
    Finek, J.
    Poprach, A.
    Melichar, B.
    Kopecky, J.
    Zemanova, M.
    Buchler, T.
    Kopeckova, K.
    Mlcoch, T.
    Dolezal, T.
    Fiala, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 387 - 387
  • [38] RELATIONSHIP BETWEEN OVERALL RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) IN CLINICAL TRIALS OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
    Jen, M. H.
    Sonksen, M.
    Hess, L.
    Bian, F.
    VALUE IN HEALTH, 2023, 26 (06) : S44 - S44
  • [39] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [40] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345